Thermostable lipid nanoparticle and methods of use thereof
The present disclosure provides, among other things, a lipid nanoparticle adjuvant composition. The present disclosure provides pharmaceutical compositions that include a stable lipid nanoparticle adjuvant and human papillomavirus (HPV) virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
1 . A lipid nanoparticle comprising:
(1) a PEG-lipid having the structure set forth in Formula II, wherein n is from 30-50;
(2) a phospholipid having the structure set forth in Formula III or Formula IIIa;
(3) the following cationic lipid: (13Z, 16Z)—N, N-dimethyl-3-nonyldocosa 13, 16-dien-1-amine; and
(4) cholesterol.
2 . The lipid nanoparticle of claim 1 , wherein the lipid nanoparticle comprises 5-15 mole % phospholipid, 25-35 mole % cholesterol, 1-2.5 mole % PEG-lipid, and 55-65 mole % (13Z, 16Z)—N, N-dimethyl-3-nonyldocosa 13, 16-dien-1-amine.